Yudai Kaneko belongs to MBL (Medical & Biological Laboratories Co.), the company that imported testing material used in this research. The authors have no conflicts of interest to declare. Masaharu Tsubokura and Yurie Kobashi received a research grant from the Pfizer Health Research Foundation outside the submitted work. This study was also supported by Medical & Biological Laboratories Co., Ltd., Shenzhen YHLO Biotech Co., Ltd., as well as the the distributor and manufacturer of the antibody measurement system (iFlash 3000). This study was supported by the Japan Agency for Medical Research and Development (No. T1 - Antibody and T-Cell Responses against SARS-CoV-2 after Booster Vaccination in Patients on Dialysis Future research should investigate the continued long-term dynamics of antibody titers and cellular immunity after the third or further vaccinations, evaluating the need for additional vaccinations for hemodialysis patients.",
By repeating the measurements over a period of two months, we clarified the chronological aspects of the acquisition of humoral immunity in dialysis patients after a booster COVID-19 vaccination most dialysis patients acquired not only humoral immunity, but also cellular immunity against SARS-CoV-2. The median IgG antibody titer reached a maximum of 3104.13 AU/mL after 16 days of booster dose, and cellular immunity was positive in 61.9% and 100% of patients with BNT162b2 and mRNA-1273 vaccination, respectively. Median neutralizing antibodies reached a maximum at 56 and 9 days after booster vaccination with BNT162b2 and mRNA-1273, respectively. The study includes 58 patients on hemodialysis. Humoral immunity was repeatedly measured for up to two months. This prospective, observational cohort study of maintenance hemodialysis patients examined IgG antibody levels against the SARS-CoV-2 spike (S1) protein, neutralizing activity, and interferon gamma levels after the third dose of the BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine.
Future research should investigate the continued long-term dynamics of antibody titers and cellular immunity after the third or further vaccinations, evaluating the need for additional vaccinations for hemodialysis patients.Ībstract = "Intensive vaccination is recommended for populations more vulnerable to COVID-19 infection, although data regarding the built of immunity after vaccination for dialysis patients are lacking.
Intensive vaccination is recommended for populations more vulnerable to COVID-19 infection, although data regarding the built of immunity after vaccination for dialysis patients are lacking.
0 kommentar(er)
